SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  June 24, 2014 (June 19, 2014)


CHEMBIO DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
0-30379
 
88-0425691
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
 
 
 
Identification Number)
 
 
3661 Horseblock Road
 
 
 
 
Medford, NY 11763
 
 
 
 
(Address of principal executive offices)
 
 
 
 
631-924-1135
 
 
 
 
(Registrant's Telephone Number)
 
 
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

 
 
 


Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company's annual stockholder meeting on June 19, 2014, stockholders elected directors of the Company to serve until the next annual meeting of stockholders or until their respective successors are elected and qualified.  Stockholders also ratified the selection of BDO USA LLP as the Company's independent registered certified accountants to audit the Company's financial statements as of and for the year ending December 31, 2014, approved an advisory vote to approve the compensation paid to the Company's named executive officers, and approved the 2014 Stock incentive Plan.  A tabulation of the matters voted on at this annual stockholder meeting is set forth below.

Proposal #1:– Election of Directors
 
Kathy L. Davis
 
Barbara D. DeBuono
 
Peter Kissinger
 
Dr. Gary Meller
 
John J. Sperzel III
For
 
         4,377,839
 
4,350,464
 
4,388,339
 
4,387,839
 
4,661,448
Withheld/Against
 
301,955
 
329,330
 
291,455
 
291,955
 
18,346
Broker non-votes
 
3,539,417
 
3,539,417
 
3,539,417
 
3,539,417
 
3,539,417

Proposal
 
Ratifying BDO USA LLP as the Company's Independent Auditors for the year ending December 31, 2013
 
Approve Compensation  paid to the Company's named Executive Officers
 
Approve 2014 Stock Incentive Plan
 
 Vote to Adjourn Or Postpone the meeting
 
Vote on Other Business
For
 
8,177,995
 
4,631,056
 
4,490,445
 
7,291,577
 
6,225,241
Withheld/Against
 
17,202
 
17,202
 
27,160
 
35,886
 
671,184
Abstain
 
24,014
 
23,678
 
155,563
 
185,651
 
99,513
Broker non-votes
 
-
 
3,547,275
 
3,546,043
 
706,097
 
1,223,273


The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.




 


 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date:  June 24, 2014                                                                                          Chembio Diagnostics, Inc.



By:    /s/ John J. Sperzel, III                                      
John J. Sperzel III
Chief Executive Officer